150 related articles for article (PubMed ID: 24526161)
1. Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.
Happold C; Roth P; Silginer M; Florea AM; Lamszus K; Frei K; Deenen R; Reifenberger G; Weller M
Mol Cancer Ther; 2014 Apr; 13(4):948-61. PubMed ID: 24526161
[TBL] [Abstract][Full Text] [Related]
2. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
6. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
[TBL] [Abstract][Full Text] [Related]
7. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
[TBL] [Abstract][Full Text] [Related]
8. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
Gaspar N; Marshall L; Perryman L; Bax DA; Little SE; Viana-Pereira M; Sharp SY; Vassal G; Pearson AD; Reis RM; Hargrave D; Workman P; Jones C
Cancer Res; 2010 Nov; 70(22):9243-52. PubMed ID: 20935218
[TBL] [Abstract][Full Text] [Related]
9. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.
Rosati SF; Williams RF; Nunnally LC; McGee MC; Sims TL; Tracey L; Zhou J; Fan M; Ng CY; Nathwani AC; Stewart CF; Pfeffer LM; Davidoff AM
Mol Cancer Ther; 2008 Dec; 7(12):3852-8. PubMed ID: 19056675
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
[TBL] [Abstract][Full Text] [Related]
11. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
12. Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
Yuki K; Natsume A; Yokoyama H; Kondo Y; Ohno M; Kato T; Chansakul P; Ito M; Kim SU; Wakabayashi T
Cancer Lett; 2009 Oct; 284(1):71-9. PubMed ID: 19457609
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Roos WP; Jöst E; Belohlavek C; Nagel G; Fritz G; Kaina B
Cancer Res; 2011 Jun; 71(12):4150-60. PubMed ID: 21493591
[TBL] [Abstract][Full Text] [Related]
14. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
15. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
16. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
18. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
19. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
20. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
Ciceroni C; Bonelli M; Mastrantoni E; Niccolini C; Laurenza M; Larocca LM; Pallini R; Traficante A; Spinsanti P; Ricci-Vitiani L; Arcella A; De Maria R; Nicoletti F; Battaglia G; Melchiorri D
Cell Death Differ; 2013 Mar; 20(3):396-407. PubMed ID: 23175182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]